FERMENTAFermenta Biotech Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Fermenta Biotech Limited, together with its subsidiaries, manufactures and markets chemicals, bulk drugs, and enzymes in India, Europe, the United States, and internationally. It provides pharmaceutical formulations and environmental solutions; rents and sells properties; and sports and health awareness/education services. The company also offers various variants of vitamin D3, including crystalline oil, resin oil, cold water dispersible, and feed grade powder for use in various applications, such as pharmaceuticals, dietary and nutritional supplements, feed, injectables, soft gel capsules, premixes, food and beverage fortification, veterinary, feed, and rodenticides; pharmaceutical ingredients comprising phenyramidol and silicon dry powder; nutritional premixes; and enzymes for use in oleochemicals, fine chemicals, active pharmaceutical ingredients, food and fragrances, leather, and biodiesel industries. In addition, it engages in the design, engineering, procurement, and construction of water and wastewater treatment plants; and offers operations and maintenance services, as well as property development business. The company was formerly known as DIL Limited. Fermenta Biotech Limited was incorporated in 1951 and is based in Thane, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on FERMENTA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • ROE: 17.7%
- • Debt/Equity: 0.28
- • Promoter holding: 70.7%
- • Price vs SMA50: above
- • 1-month vs NIFTY: +7.3% relative
- • 3-month return: +45.4%
Bull case
- • ROE: 17.7%
- • Debt/Equity: 0.28
- • Promoter holding: 70.7%
- • Price vs SMA50: above
Bear case
- • Revenue growth: -10.6% YoY
- • Profit growth: -55.3% YoY
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Revenue growth: -10.6% YoY
- • Profit growth: -55.3% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹26.46). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.